Latest Cancer immunotherapy Stories
Ex-Vivo Manipulation of Autologous Hematopoietic Stem Cells Complements Dendritic Cell-based Vaccine Platform; Potential to Develop Single-Agent and Combination Immunotherapeutics LOS
-Conference Call and Webcast on September 12, 2014 at 8:30 a.m. ET, 5:30 a.m. PT- MENLO PARK, Calif. and LONDON, Sept.
The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.
Unique Multivalent WT1 Vaccine to be developed across hematological malignancies and solid tumors NEW YORK, Sept.
Initial Closing is for $10 Million FREDERICK, Md., Aug.
HPV Immune Therapy VGX-3100 to Advance into Phase III PLYMOUTH MEETING, Penn., Aug. 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
Patented Technology Enables Accurate Delivery of a Chemotherapeutic Drug to Targeted Tumor Cells, Reducing Drug-related Toxicity without Sacrificing Therapeutic Impact SYDNEY, Aug.
TAMPA, Fla., Aug.
Study Correlates Immune Response with Improved Survival in Prostate Cancer Patients after Receiving the Antigen Express Novel Immunotherapeutic AE37 WORCESTER, Mass.
- A transitional zone between two communities containing the characteristic species of each.